Anti-CD19 chimeric antigen receptor T cell therapy(TriArm Therapeutics)

N/A

Report date: 2023/10/23 14:12:18

Base Information

Drug NameAnti-CD19 chimeric antigen receptor T cell therapy(TriArm Therapeutics)
Drug Alias NameCD19-mbIL15-CAR-T cell therapy(TriArm Therapeutics)RPM CD19-mbIL15-CAR-T Cell therapy(TriArm Therapeutics)
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsHematologic NeoplasmsLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesTriArm Therapeutics (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTriArm Therapeutics (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A